| Date Filed | Type | Description |
| 02/14/2020 |
SC 13G/A
| ARCH VENTURE FUND V LP has filed a Schedule 13D for – Exit Filing)* Impinj, Inc. |
| 02/14/2019 |
SC 13G/A
| ARCH VENTURE FUND V LP reports a 6.4% stake in Impinj, Inc. |
| 02/02/2018 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2017 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 08/03/2011 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 11/09/2010 |
SC 13G/A
| ARCH VENTURE FUND V LP has filed a Schedule 13D for TRUBION PHARMACEUTICALS, INC. |
| 02/11/2008 |
SC 13G/A
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals [amend] |
| 01/04/2008 |
SC 13D/A
| ARCH VENTURE FUND V LP reports a 17.2% stake in NeurogesX, Inc. |
| 05/16/2007 |
SC 13D
| ARCH VENTURE FUND V LP reports a 20.3% stake in NeurogesX, Inc. |
| 02/14/2007 |
SC 13G/A
| ARCH VENTURE FUND V LP has filed a Schedule 13D for Alnylam Pharmaceuticals, Inc. |
| 02/14/2007 |
SC 13G
| ARCH VENTURE FUND V LP reports a 13.4% stake in TRUBION PHARMACEUTICALS, INC. |
| 04/13/2006 |
SC 13D/A
| ARCH VENTURE FUND V LP has filed a Schedule 13D for CYCLACEL PHARMACEUTICALS, INC. |
| 02/14/2006 |
SC 13G/A
| ARCH VENTURE FUND V LP reports a 5.8% stake in ALNYLAM PHARMACEUTICALS, INC. |
| 02/14/2005 |
SC 13G/A
| ARCH VENTURE FUND V LP reports a 9.4% stake in ALNYLAM PHARMACEUTICALS, INC. |
| 11/12/2004 |
SC 13D
| ARCH VENTURE FUND V LP reports a 18.5% stake in XCYTE THERAPIES, INC. |
| 06/10/2004 |
SC 13G
| ARCH VENTURE FUND V LP reports a 10.4% stake in ALNYLAM PHARMACEUTICALS, INC. |